ASX - By Stock
|
LTP |
Re:
Ann: SPONTAN achieves positive clinical study results
|
|
Lefevre
|
41 |
8.2K |
11 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
41
|
8.2K
|
11
|
|
ASX - By Stock
|
CC9 |
Re:
Wheres The Bottom
|
|
Lefevre
|
4 |
453 |
2 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
4
|
453
|
2
|
|
ASX - By Stock
|
AGN |
Re:
Ann: DSMB Confirms Safety of First Patients Dosed
|
|
Lefevre
|
21 |
8.0K |
12 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
21
|
8.0K
|
12
|
|
ASX - By Stock
|
AGN |
Re:
AGN Media thread
|
|
Lefevre
|
84 |
27K |
13 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
84
|
27K
|
13
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Suspension from Quotation
|
|
Lefevre
|
30 |
7.7K |
11 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
30
|
7.7K
|
11
|
|
ASX - By Stock
|
AM7 |
Re:
Ann: Capital Raising
|
|
Lefevre
|
2 |
672 |
0 |
04/06/24 |
04/06/24 |
ASX - By Stock
|
2
|
672
|
0
|
|
IPOs
|
|
Re:
GYG - Guzman y gomez
|
|
Lefevre
|
9 |
5.9K |
3 |
01/06/24 |
01/06/24 |
IPOs
|
9
|
5.9K
|
3
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Suspension from Quotation
|
|
Lefevre
|
5 |
1.6K |
7 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
5
|
1.6K
|
7
|
|
ASX - By Stock
|
CYC |
Re:
Ann: Cleasing Statement - Placement
|
|
Lefevre
|
1 |
369 |
0 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
1
|
369
|
0
|
|
ASX - By Stock
|
AGN |
Re:
Ann: DSMB Confirms Safety of First Patients Dosed
|
|
Lefevre
|
21 |
8.0K |
10 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
21
|
8.0K
|
10
|
|
ASX - By Stock
|
AGN |
Re:
Ann: DSMB Confirms Safety of First Patients Dosed
|
|
Lefevre
|
21 |
8.0K |
2 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
21
|
8.0K
|
2
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Pause in Trading
|
|
Lefevre
|
41 |
7.3K |
1 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
41
|
7.3K
|
1
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Pause in Trading
|
|
Lefevre
|
41 |
7.3K |
4 |
30/05/24 |
30/05/24 |
ASX - By Stock
|
41
|
7.3K
|
4
|
|
IPOs
|
Lithium |
Re:
Phoenix Water - PXW - Lithium - 100x
|
|
Lefevre
|
1.8K |
1.3M |
5 |
29/05/24 |
29/05/24 |
IPOs
|
1.8K
|
1.3M
|
5
|
|
ASX - By Stock
|
LTP |
Re:
Ann: LTR Pharma to List on the ASX
|
|
Lefevre
|
145 |
49K |
6 |
28/05/24 |
28/05/24 |
ASX - By Stock
|
145
|
49K
|
6
|
|
IPOs
|
|
Re:
Nviso AI ipo
|
|
Lefevre
|
245 |
278K |
2 |
27/05/24 |
27/05/24 |
IPOs
|
245
|
278K
|
2
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Company Presentation - Investor Insights
|
|
Lefevre
|
77 |
19K |
8 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
77
|
19K
|
8
|
|
ASX - By Stock
|
CC9 |
Re:
Ann: Chairman Resignation and Withdrawal of Resolution at AGM
|
|
Lefevre
|
1 |
496 |
1 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
1
|
496
|
1
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Final Patients dosed in SPONTAN pivotal study
|
|
Lefevre
|
109 |
29K |
5 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
109
|
29K
|
5
|
|
ASX - By Stock
|
AGN |
Re:
Ann: ARG-007 Reduces Effects of TBI in Preclinical Study
|
|
Lefevre
|
16 |
5.8K |
6 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
16
|
5.8K
|
6
|
|
ASX - By Stock
|
AGN |
Re:
Ann: ARG-007 Reduces Effects of TBI in Preclinical Study
|
|
Lefevre
|
16 |
5.8K |
14 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
16
|
5.8K
|
14
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Change in substantial holding
|
|
Lefevre
|
4 |
1.2K |
3 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
4
|
1.2K
|
3
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Argenica Successfully Completes $12.0m Placement
|
|
Lefevre
|
59 |
15K |
6 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
59
|
15K
|
6
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Corporate Presentation
|
|
Lefevre
|
37 |
9.2K |
3 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
37
|
9.2K
|
3
|
|
ASX - By Stock
|
AGN |
Re:
AGN Media thread
|
|
Lefevre
|
84 |
27K |
4 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
84
|
27K
|
4
|
|
ASX - By Stock
|
GTI |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Lefevre
|
11 |
3.9K |
4 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
11
|
3.9K
|
4
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Corporate Presentation
|
|
Lefevre
|
37 |
9.2K |
2 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
37
|
9.2K
|
2
|
|
IPOs
|
Lithium |
Re:
Phoenix Water - PXW - Lithium - 100x
|
|
Lefevre
|
1.8K |
1.3M |
3 |
14/04/24 |
14/04/24 |
IPOs
|
1.8K
|
1.3M
|
3
|
|
ASX - By Stock
|
AGN |
Re:
AGN Media thread
|
|
Lefevre
|
84 |
27K |
1 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
84
|
27K
|
1
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Trading Halt
|
|
Lefevre
|
23 |
6.3K |
9 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
23
|
6.3K
|
9
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Trading Halt
|
|
Lefevre
|
23 |
6.3K |
2 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
23
|
6.3K
|
2
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Trading Halt
|
|
Lefevre
|
23 |
6.3K |
11 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
23
|
6.3K
|
11
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Trading Halt
|
|
Lefevre
|
23 |
6.3K |
13 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
23
|
6.3K
|
13
|
|
IPOs
|
Lithium |
Re:
Phoenix Water - PXW - Lithium - 100x
|
|
Lefevre
|
1.8K |
1.3M |
3 |
09/04/24 |
09/04/24 |
IPOs
|
1.8K
|
1.3M
|
3
|
|
ASX - By Stock
|
AGN |
Re:
General Discussions
|
|
Lefevre
|
96 |
34K |
2 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
96
|
34K
|
2
|
|
ASX - By Stock
|
EVR |
Re:
Ann: Retraction of Metal Equivalents
|
|
Lefevre
|
69 |
18K |
3 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
69
|
18K
|
3
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Change in substantial holding
|
|
Lefevre
|
3 |
1.2K |
2 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
3
|
1.2K
|
2
|
|
ASX - By Stock
|
ORA |
Re:
Ann: ORA - FY24 Trading Update
|
|
Lefevre
|
31 |
18K |
6 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
31
|
18K
|
6
|
|
ASX - By Stock
|
EVR |
Re:
Ann: Retraction of Metal Equivalents
|
|
Lefevre
|
69 |
18K |
5 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
69
|
18K
|
5
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
Lefevre
|
49 |
15K |
11 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
49
|
15K
|
11
|
|
ASX - By Stock
|
AGN |
Re:
Ann: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
|
|
Lefevre
|
49 |
15K |
9 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
49
|
15K
|
9
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Change in substantial holding
|
|
Lefevre
|
3 |
1.2K |
3 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
3
|
1.2K
|
3
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Corporate Presentation
|
|
Lefevre
|
37 |
9.2K |
4 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
37
|
9.2K
|
4
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Corporate Presentation
|
|
Lefevre
|
37 |
9.2K |
4 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
37
|
9.2K
|
4
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Corporate Presentation
|
|
Lefevre
|
37 |
9.2K |
1 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
37
|
9.2K
|
1
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Corporate Presentation
|
|
Lefevre
|
37 |
9.2K |
6 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
37
|
9.2K
|
6
|
|
ASX - By Stock
|
AGN |
Re:
Ann: FDA Grants Rare Pediatric Disease Designation For HIE
|
|
Lefevre
|
18 |
5.3K |
13 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
18
|
5.3K
|
13
|
|
ASX - By Stock
|
EVR |
Re:
Ann: 332M Drilled from Near Surface at 1.36% Copper Equivalent
|
|
Lefevre
|
33 |
9.6K |
0 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
33
|
9.6K
|
0
|
|
ASX - By Stock
|
EVR |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
Lefevre
|
8 |
1.7K |
1 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
8
|
1.7K
|
1
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Investor Presentation
|
|
Lefevre
|
11 |
3.8K |
3 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
11
|
3.8K
|
3
|
|